Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

The US Food and Drug Administration (FDA) has announced it has approved colon cancer drug ... Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

That initial collaboration resulted in Sanofi licensing in a first drug candidate in 2019 for oncology and inflammatory diseases and – given the scale of the expanded agreement – the big ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...

Sanofi Oncology global head Olivier Nataf stated ... Sarclisa's non-proprietary name in the US is isatuximab-irfc, following US Food and Drug Administration guidance for the industry on ...

In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...